The role of HOXC6 in prostate cancer development

Prostate

Volumn 75, Issue 16, 2015, Pages 1868-1876

  Hamid, Agus Rizal A H ^a,b,c   Hoogland, A Marije ^d   Smit, Frank ^e   Jannink, Sander ^e   Van Rijt Van De Westerlo, Cindy ^a,b   Jansen, Cornelius F J ^a,b   Van Leenders, Geert J L H ^d   Verhaegh, Gerald W ^a,b   Schalken, Jack A ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e NovioGendix   (Netherlands)

Author keywords

androgens; homeobox gene; prostate cancer; urinary biomarker

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; ENZALUTAMIDE; HOX PROTEIN; HOXC6 PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; HOXC6 PROTEIN, HUMAN;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HOX GENE; HOXC6 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM CELL; PROSTATECTOMY; PROTEIN EXPRESSION; UPREGULATION; URINALYSIS; ADENOCARCINOMA; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR;

ADENOCARCINOMA; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MALE; NEOPLASM GRADING; PROGNOSIS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; UP-REGULATION;

EID: 84944441094     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23065     Document Type: Article

References (24)

1. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM,. Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med 2012; 4 (127): 127rv123.
2. Sartori DA, Chan DW,. Biomarkers in prostate cancer: What's new? Curr Opin Oncol 2014; 26 (3): 259-264.
3. Martinez-Pineiro L, Schalken JA, Cabri P, Maisonobe P, de la Taille A,. Triptocare Study G. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. BJU international 2014; 114 (4): 608-616.
4. van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA,. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: A randomized, open-label, parallel-group pilot study. Prostate 2009; 69 (15): 1624-1634.
5. Leyten GH, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Schalken JA,. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res 2015; 21 (13): 3061-3070.
6. Hombria JC, Lovegrove B,. Beyond homeosis-HOX function in morphogenesis and organogenesis. Differentiation 2003; 71 (8): 461-476.
7. Huang L, Pu Y, Hepps D, Danielpour D, Prins GS,. Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Endocrinology 2007; 148 (3): 1235-1245.
8. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, Partin AW, Shanmugam V, Izatt T, Sinari S, Craig DW, Zheng SL, Walsh PC, Montie JE, Xu J, Carpten JD, Isaacs WB, Cooney KA,. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366 (2): 141-149.
9. Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, Cannon-Albright LA, Teerlink CC, Camp NJ, Johnson AM, Zuhlke KA, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Maier C, Luedeke M, Vogel W, Schleutker J, Wahlfors T, Tammela T, Schaid D, McDonnell SK, DeRycke MS, Cancel-Tassin G, Cussenot O, Wiklund F, Gronberg H, Eeles R, Easton D, Kote-Jarai Z, Whittemore AS, Hsieh CL, Giles GG, Hopper JL, Severi G, Catalona WJ, Mandal D, Ledet E, Foulkes WD, Hamel N, Mahle L, Moller P, Powell I, Bailey-Wilson JE, Carpten JD, Seminara D, Cooney KA, Isaacs WB,. International consortium for prostate cancer G. HOXB13 is a susceptibility gene for prostate cancer: Results from the international consortium for prostate cancer genetics (ICPCG). Hum Genet 2013; 132 (1): 5-14.
10. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C, Kuster J, Schott W, Staehler G, Kretzler M, Hollstein M, Grone HJ,. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: A gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002; 160 (6): 2169-2180.
11. Miller GJ, Miller HL, van Bokhoven A, Lambert JR, Werahera PN, Schirripa O, Lucia MS, Nordeen SK,. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res 2003; 63 (18): 5879-5888.
12. Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, Laycock N, Amin MB, Carney JK, Marshall FF, Petros JA, Moreno CS,. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 2005; 24 (1): 188-198.
13. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA,. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 2011; 17 (7-8): 657-664.
14. Hamid AR, Pfeiffer MJ, Verhaegh GW, Schaafsma E, Brandt A, Sweep FC, Sedelaar JP, Schalken JA,. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. Mol Med 2012; 18: 1449-1455.
15. Roobol MJ, Kirkels WJ, Schroder FH,. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 2003; 92 (Suppl 2): 48-54.
16. Schroder FH, Hugosson J, Roobol M, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, Kwast THvd, Blijenberg BG, Moss SM, Koning HJd, Auvinen A,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
17. Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schroder FH, Wildhagen MF, van Leenders GJ,. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 2012; 25 (3): 471-479.
18. Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, Mulders PF, Jannink SA, Schalken JA,. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol 2014; 191 (4): 1132-1138.
19. Hessels D, Schalken JA,. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009; 6 (5): 255-261.
20. Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S,. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23 (8): 1061-1067.
21. Monga N, Sayani A, Rubinger DA, Wilson TH, Su Z,. The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses. Can Urol Assoc J 2013; 7 (3-4): E161-E167.
22. Traish AM, Mulgaonkar A, Giordano N,. The dark side of 5alpha-reductase inhibitors' therapy: Sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol 2014; 55 (6): 367-379.
23. Vinarskaja A, Yamanaka M, Ingenwerth M, Schulz WA,. DNA methylation and the HOXC6 paradox in prostate cancer. Cancers 2011; 3 (4): 3714-3725.
24. Ploussard G, de la Taille A,. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7 (2): 101-109.